Last Price$2.53NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.50 (10)
Ask (Size)$2.54 (2)
Day Low / HighN/A - N/A
Volume480.3 K

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Aravive Inc ( NASDAQ )

Price: $2.53
Change: -0.56 (18.12%)
Volume: 480.3 K
4:00PM ET 12/03/2021

Calithera Biosciences Inc ( NASDAQ )

Price: $0.72
Change: -0.08 (10.25%)
Volume: 1.0 M
4:00PM ET 12/03/2021

Eloxx Pharmaceuticals Inc ( NASDAQ )

Price: $0.62
Change: -0.10 (14.31%)
Volume: 1.3 M
4:00PM ET 12/03/2021

OpGen Inc ( NASDAQ )

Price: $1.38
Change: -0.12 (7.69%)
Volume: 1.1 M
4:00PM ET 12/03/2021

NanoViricides Inc ( NYSE MKT LLC )

Price: $4.46
Change: -0.09 (1.98%)
Volume: 312.1 K
8:00PM ET 12/03/2021

Read more news Recent News

Aravive Reports Positive Update on Clear Cell Renal Cell Carcinoma Treatment
10:03AM ET 11/12/2021 MT Newswires

Aravive (ARAV) reported Friday positive new data from its phase 1b trial evaluating its AVB-500 batiraxcept candidate in combination with cabozantinib in...

-- Earnings Flash (ARAV) ARAVIVE Posts Q3 Revenue $2.4M
4:01PM ET 10/28/2021 MT Newswires


--Piper Sandler Adjusts Aravive's Price Target to $18 From $20, Maintains Overweight Rating
12:49PM ET 8/06/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (ARAV) ARAVIVE Posts Q2 Revenue $3.8M
7:14AM ET 8/05/2021 MT Newswires


View all Commentary and Analysis

Numenor Capital Portfolio Update #1
1:48PM ET 4/06/2021 Seeking Alpha

Unless Early Ovarian Data Is Oversold, Aravive Is Significantly Undervalued
8:59AM ET 3/18/2021 Seeking Alpha

Aravive (ARAV) Investor Presentation - Slideshow
12:56PM ET 3/12/2021 Seeking Alpha

Aravive: Pipeline-In-A-Pill In Oncology
9:48AM ET 12/28/2020 Seeking Alpha

Company Profile

Business DescriptionAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. View company web site for more details
AddressRiver Oaks Tower
Houston, Texas 77098
Number of Employees14
President, Chief Executive Officer & DirectorGail Frances McIntyre
Chief Financial OfficerVinay Shah
Chief Medical OfficerReshma Rangwala
Vice President-Clinical OperationsAmy Franke

Company Highlights

Price Open$3.13
Previous Close$3.09
52 Week Range$2.41 - 9.95
Market Capitalization$53.1 M
Shares Outstanding21.0 M
SectorHealth Technology
Next Earnings Announcement03/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.58
Beta vs. S&P 500N/A
Revenue$1.4 M
Net Profit Margin-249.06%
Return on Equity-51.44%

Analyst Ratings as of 10/29/2021

Consensus RecommendationConsensus Icon
Powered by Factset